Uncovering Mechanisms Associated With ADT Resistance in Prostate Cancer
In this video, David Goodrich, PhD, of Roswell Park Cancer Institute in Buffalo, discusses treatment resistance and disease relapse in prostate cancer.
In this video, David Goodrich, PhD, of Roswell Park Cancer Institute in Buffalo, discusses treatment resistance and disease relapse in prostate cancer.
Dr. Goodrich presented the possible underlying mechanisms associated with androgen deprivation therapy (ADT) resistance and suggests an epigenetic approach for extending the clinical benefits of ADT at the 2017 American Society for Cancer Research (AACR) Annual Meeting, held April 1–5 in Washington, DC.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Navigating Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer
A patient case of a 50-year-old man with hormone-sensitive prostate cancer sparked a debate among oncologists regarding the best course of action.
